Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B2OC
|
||||
| Former ID |
DCL000968
|
||||
| Drug Name |
R-sibutramine metabolite
|
||||
| Indication | Depression; Attention deficit hyperactivity disorder [ICD9: 311, 314.00, 314.01; ICD10:F30-F39, F90] | Discontinued in Phase 2 | [1] | ||
| Company |
Sepracor
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Modulator | ||
| Sodium-dependent serotonin transporter | Target Info | Modulator | |||
| KEGG Pathway | Serotonergic synapse | ||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathway | |||||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
| SIDS Susceptibility Pathways | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.